Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
conatumumab + mFOLFOX6 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
conatumumab + mFOLFOX6 + bevacizumab is an investigational multi-agent combination regimen used in clinical trials primarily for metastatic colorectal cancer. This regimen includes: - **conatumumab**, a monoclonal antibody targeting death receptor 5 (DR5) to induce apoptosis in tumor cells. - **mFOLFOX6**, a chemotherapy regimen containing folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin that interferes with DNA synthesis and function, leading to cell death. - **bevacizumab**, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and tumor vascularization[2][4][5][6]. The combination is being studied to improve outcomes for patients with advanced or metastatic colorectal cancer.
- Brand names
- bevacizumab
- Other names
- folinic acid + fluorouracil + oxaliplatin + conatumumab + bevacizumab
02
Targets
TS (Thymidylate synthase)TNFRSF10B (DR5)VEGFA (Vascular endothelial growth factor A)DNADPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on conatumumab + mFOLFOX6 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on conatumumab + mFOLFOX6 + bevacizumab.